In this context, this study reports, for the first time, an anti-migratory, anti-invasive and anti-thrombotic effect of venetoclax, which could indicate its use as a new molecular-targeted treatment for CRC and other hepsin-overexpressing tumors. This evidence concerns the gene HPN and colorectal carcinoma.